0001867066 false 0001867066 2023-05-16 2023-05-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares















Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): May 16, 2023


Journey Medical Corporation

(Exact Name of Registrant as Specified in Charter)


Delaware  001-41063  47-1879539
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)  (IRS Employer Identification No.)


9237 E Via de Ventura Blvd., Suite 105

Scottsdale, AZ 85258

(Address of Principal Executive Offices)


(480) 434-6670

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act.


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.


¨ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock DERM Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 1.01.Entry into a Material Definitive Agreement.


Journey Medical Corporation (the “Company”) and its subsidiary, JG Pharma, Inc. (“JGP”), are party to that certain Loan and Security Agreement, dated March 31, 2021 (as amended, the “EWB Facility”), with East West Bank (“EWB”) under which EWB originally made a $7.5 million line of credit available to the Company. On January 12, 2022, the EWB Facility was amended to increase the borrowing capacity of the revolving line of credit to $10.0 million and add a term loan not to exceed $20.0 million. The Company subsequently borrowed the full $20 million under the term loan. On May 16, 2023, the Company entered into the Fifth Amendment to Loan and Security Agreement with EWB and JGP (the “2023 Amendment”). Under the 2023 Amendment, the Company agreed to pay off $10 million of the term loan upon the closing of the 2023 Amendment. The term loan previously had an interest-only payment period through January 12, 2024, after which the outstanding balance of the term loan was to have been payable in equal monthly installments of principal, plus all accrued interest, through the term loan maturity date. The 2023 Amendment revises the maturity date of the term loan from January 12, 2026 to July 1, 2024 and provides that the Company is no longer required to make monthly installments of principal of the term loan, and instead, is required to make interest-only payments until the maturity date, at which time all principal and all accrued but unpaid interest will be due. The Company may elect to prepay all or any part of the term loan without penalty or premium, but the Company may not re-borrow any amount, once repaid. The 2023 Amendment removed the revolving line of credit as of the effective date of the 2023 Amendment. There were no amounts outstanding under the revolving line of credit as of such date. The EWB Facility included customary financial covenants such as collateral ratios and minimum liquidity provisions. Upon the effectiveness of the 2023 Amendment, all of these financial covenants were removed, except for the minimum liquidity ratio, and certain other nonfinancial covenants were added. To ensure compliance with the minimum liquidity ratio, the Company is now required to maintain $8.75 million in deposit accounts at EWB that are subject to assignment to EWB until August 31 2023, when this amount increases to $10 million.


Item 2.02.Results of Operations and Financial Condition.


On May 22, 2023, the Company issued a press release to provide a corporate update and to announce its financial results for the three months ended March 31, 2023. A copy of such press release is being furnished as Exhibit 99.1 to this report.


The information in this Item 2.02 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 attached hereto shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.


Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.


The disclosures set forth in Item 1.01 of this Current Report on Form 8-K are incorporated by reference herein.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.


The following exhibits are furnished herewith:





Press release issued by Journey Medical Corporation, dated May 22, 2023.

104   Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Journey Medical Corporation

Date: May 22, 2023

By:/s/ Claude Maraoui
  Claude Maraoui
  Chief Executive Officer, President and Director